HPK1 Dysregulation‐Associated NK Cell Dysfunction and Defective Expansion Promotes Metastatic Melanoma Progression

Author:

Choi Woo Seon1,Kwon Hyung‐Joon1,Yi Eunbi1,Lee Haeun1,Kim Jung Min1,Park Hyo Jin1,Choi Eun Ji2,Choi Myoung Eun2,Sung Young Hoon3,Won Chong Hyun2,Sung Chang Ohk4,Kim Hun Sik1ORCID

Affiliation:

1. Department of Microbiology Stem Cell Immunomodulation Research Center Asan Medical Center University of Ulsan College of Medicine Seoul 05505 Republic of Korea

2. Department of Dermatology Asan Institute for Life Sciences Asan Medical Center University of Ulsan College of Medicine Seoul 05505 Republic of Korea

3. Department of Cell and Genetic Engineering Asan Medical Center University of Ulsan College of Medicine Seoul 05505 Republic of Korea

4. Department of Pathology Asan Medical Institute of Convergence Science and Technology Asan Medical Center University of Ulsan College of Medicine Seoul 05505 Republic of Korea

Abstract

AbstractDistant metastasis, the leading cause of cancer death, is efficiently kept in check by immune surveillance. Studies have uncovered peripheral natural killer (NK) cells as key antimetastatic effectors and their dysregulation during metastasis. However, the molecular mechanism governing NK cell dysfunction links to metastasis remains elusive. Herein, MAP4K1 encoding HPK1 is aberrantly overexpressed in dysfunctional NK cells in the periphery and the metastatic site. Conditional HPK1 overexpression in NK cells suffices to exacerbate melanoma lung metastasis but not primary tumor growth. Conversely, MAP4K1‐deficient mice are resistant to metastasis and further protected by combined immune‐checkpoint inhibitors. Mechanistically, HPK1 restrains NK cell cytotoxicity and expansion via activating receptors. Likewise, HPK1 limits human NK cell activation and associates with melanoma NK cell dysfunction couples to TGF‐β1 and patient response to immune checkpoint therapy. Thus, HPK1 is an intracellular checkpoint controlling NK‐target cell responses, which is dysregulated and hijacked by tumors during metastatic progression.

Funder

National Research Foundation of Korea

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3